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Raffaele Califano2, Glen Clack4, Andrew Hughes3,4 and Caroline Dive1,3
The incidence of melanoma is increasing worldwide. Advances in targeted agents and immunotherapy have
improved outcomes in metastatic disease, but biomarkers are required to optimize treatment. We determined the
prevalence of circulating tumor cells (CTCs) and explored their utility as prognostic and pharmacodynamic
biomarkers. A total of 101 patients with metastatic cutaneous melanoma were recruited prospectively. CTC
number was determined using the CellSearch platform and melanoma kits in samples taken at baseline and
serially during treatment. CTC numbers ranged between 0 and 36 per 7.5ml blood; 26% of patients hadX2 CTCs.
Baseline CTC number was prognostic for median overall survival (OS) in univariate analysis (2.6 vs. 7.2 months
(Po0.011) for patients with X2 CTCs vs. o2 CTCs, respectively). In multivariate analysis, CTC number was an
independent prognostic biomarker of OS (hazard ratio (HR) 2.403, 95% confidence interval (CI) 1.303–4.430,
P¼ 0.005). Patients receiving treatment in whom CTC number remained X2 CTCs during treatment had shorter
median OS than those who maintained o2 CTCs (7 vs. 10 months, HR 0.34, 95% CI 0.14–0.81, log-rank test
P¼ 0.015). In conclusion, CTC number in metastatic cutaneous melanoma patients is prognostic for OS with a
cutoff of 2 CTCs per 7.5ml blood. CTC number measured before and throughout treatment provided additional
prognostic information. Larger studies are warranted to confirm CTC biomarker utility in melanoma patients.
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INTRODUCTION
Melanoma is the most serious form of skin cancer and the
incidence is increasing worldwide. Approximately 80% of
patients are cured with surgery. The prognosis of patients with
metastatic disease has improved with targeted agents and
immunotherapy (Hodi et al., 2010; Chapman et al., 2011), but
there are few long-term survivors. Advances in molecular
subtyping of melanoma have identified patient subgroups with
specific genetic aberrations (Davies et al., 2002; Curtin et al.,
2005, 2006). This has in turn guided the development of
targeted therapies such as the BRAF selective inhibitor
vemurafenib, which has been shown to improve survival
when compared with standard chemotherapy with
dacarbazine in patients with BRAF mutant tumors (Chapman
et al., 2011). However, subsequent drug resistance and
disease progression are observed in the majority of patients
(Ribas and Flaherty, 2011). Ipimulimab, a cytotoxic
T-lymphocyte antigen 4 inhibitor, has also improved median
overall survival (OS) in metastatic disease, with a subgroup of
patients being long-term survivors. Patient selection is
hindered by the absence of a predictive biomarker to stratify
patients (Hodi et al., 2010).
Assessment of genetic aberrations and evolving tumor
biology, particularly with respect to emergent mechanisms
of drug resistance, is thus increasingly relevant. Longitudinal
monitoring of patients to report or, better still, give an early
warning of treatment failures would be beneficial. However,
as obtaining tumor biopsy before and after treatment is
challenging and not without risk, more minimally invasive
approaches are sought.
Circulating tumor cells (CTCs) hold potential as prognostic,
predictive, and pharmacodynamic biomarkers. Although mel-
anoma was the first solid tumor in which CTCs were detected
(using PCR) (Smith et al., 1991), lack of validated and
standardized methodology hampered qualification of CTCs
as a biomarker in clinical trials (Nezos et al., 2009). CTC
number determined using the CellSearch platform (Veridex,
Raritan, NJ) is prognostic for OS in metastatic lung, breast,
prostate, and colorectal carcinomas (Cristofanilli et al., 2004;
Cohen et al., 2008; de Bono et al., 2008; Hou et al., 2009,
2012; Krebs et al., 2011), where the ‘‘cutoff’’ (CTC number per
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7.5 ml blood) depends on the tumor type and prevalence of
CTCs. A melanoma-specific CellSearch CTC kit developed
recently uses Melcam and high molecular weight–melanoma-
associated antibody (HMW-MAA) for melanoma CTC capture
and detection, respectively (Rao et al., 2011).
Here, we evaluate the prevalence, clinical significance, and
biomarker potential of melanoma CTCs using this technology
in patients with metastatic disease. Our primary objective was
to evaluate the incidence and prognostic significance on OS of
CTC number at baseline in metastatic cutaneous melanoma
patients. Exploratory end points were pharmacodynamic
changes in CTC number and prognostic significance of these
changes. Our overall goal was to evaluate the biomarker
utility of CTCs as a prelude to their incorporation in clinical
trials, where they might also provide opportunity for molecular
analyses to facilitate patient stratification and monitoring of
development of drug resistance.
RESULTS
Patient demographics
Between December 2009 and December 2011, 101 patients
were recruited into this study and their clinical characteristics
are shown in Table 1. The majority of patients had stage M1C
disease and performance status (PS) 0–1. BRAF mutational
status was assessed in approximately two-thirds of patients and
approximately half of them had a mutation detected. Sixty-one
patients had died by the time of analysis and one was lost to
follow-up. Average follow-up for the remaining 39 patients
was 5.9±5.2 months (SD, range 0.3–20 months). Of the
patients studied, 68 were treatment naive and went on to
receive treatment, 17 patients received no treatment, and 16
patients had previously received first-line treatment and went
on to receive second-line therapy.
Analysis of CTC enumeration accuracy using the b-expectation
tolerance interval (BETI) approach
Validation experiments were conducted to determine the
analytical accuracy of CellSearch CTC enumeration at low
(1–10) CTC numbers. Analysts scored the same image galleries
generated from 20 different samples of melanoma patients
with low CTC counts, and the results were evaluated using the
BETI approach (see Supplementary Data online for details).
The analytical accuracy achieved by the two analysts who
performed the CTC analysis reported herein was high with a
95% probability of a BETI (for total error) of o30%. These
data support our contention that melanoma CTCs can be
reliably enumerated at numbers as low as 2 CTCs in 7.5 ml
blood using the CellSearch platform.
Prevalence of CTCs at baseline
A CTC count of zero and very rarely 1 CTC has been reported
in 55 healthy volunteers using this melanoma-specific kit and
the CellSearch platform (Rao et al., 2011). The range of CTC
number per 7.5 ml blood detected at baseline was 0–36
(n¼ 101, mean 2, median 0); 60% of patients had no CTCs
and 40% had one or more CTCs. Figure 1a–e shows
representative images of melanoma CTCs from five patients.
To be assigned as a CTC, cells must have a 4’,6-diamidino-2-
phenylindole–stained nucleus (pseudocolored pink) and
HMW-MAA staining (pseudocolored green) in the absence
of leukocyte and endothelial marker expression (CD45/CD34
staining, respectively). The size of melanoma cells thus
detected is variable (the longest cell diameter ranges between
6 and 22mm), with some CTCs considerably larger than those
staining for CD45/CD34. Contaminant cells shown in
Figure 1f and g stained positively with the CD45/CD34
Table 1. Patient demographics
Clinical characteristic Number %
Age at baseline, years
Median 60
Range 32–89
Sex
Male 53 52.5
Female 48 47.5
Stage at enrollment
M1a 4 4
M1b 18 17.8
M1c 79 78.2
Period of time with metastases
Median 5 Months
Range 1–72 Months
WHO performance status
0 41 40.6
1 45 44.6
2 12 11.9
3 1 1
LDH
Normal (p550) 65 64
High (4550) 36 36
BRAF mutation
Wild type 38 38
Braf mutation 32 32
Unknown 31 30
Treatment
Dacarbazine/temozolamide 21 20.8
BRAF/MEK inhibitor 20 19.8
Ipimulimab 7 6.9
Other 9 8.9
Radiotherapy 1 1
Stage of treatment
First-line treatment 68 66.7
Second-line treatment 16 15.7
Untreated 17 16.7
Abbreviations: LDH, lactate dehydrogenase; MEK, MAPK/ERK kinase;
WHO, World Health Organization.
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Figure 1. Representative cell images obtained with the Veridex platform using the melanoma kit. (a–e) Representative pseudocolored images of melanoma
circulating tumor cells (CTCs) from five patients with a 4’,6-diamidino-2-phenylindole (DAPI)-stained nucleus (pink), positive staining for the melanoma marker
high molecular weight–melanoma-associated antibody (HMW-MAA; green) in the absence of staining for CD45/CD34 markers of leukocytes and endothelial cells,
respectively. PE, phycoerythrin. f, g) Representative pseudocolored images of patients’ leukocytes or endothelial cells that have a DAPI-stained nucleus (pink), and
stain positively for CD45/CD34 (green) and negatively for HMW-MAA. The images shown are more likely to be leukocytes than endothelial cells because of the
smaller size of the former.
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antibody cocktail, the relatively small size of these cells
(7–8mm) suggests that they are leukocytes.
The optimal CTC cutoff value for prognostication and correlation
with clinical characteristics
A cutoff of 2 CTCs provided the largest discrimination on the
basis of median OS, i.e., a clear prognostic distinction
between patients (see Supplementary Data online). This cutoff
was applied to categorize patients into ‘‘favorable’’ (o2CTCs;
n¼75) and unfavorable (X2 CTCs; n¼ 26) groups. Table 2
compares CTC number at baseline with clinical characteris-
tics. Of the clinical factors, only lactate dehydrogenase (LDH;
P¼0.001) and PS (P¼0.002) showed significant association
with CTC number. Whether the patients had received treat-
ment with first- or second-line treatment did not significantly
affect the prevalence of CTCs or the selection of a CTC cutoff
of X2 CTCs (Table 2).
Prognostic significance of baseline CTC number
The Kaplan–Meier analysis was applied to determine the
prognostic significance of baseline CTC number (Figure 2a).
Patients with o2 CTCs had significantly longer median OS
than patients with X2 CTCs (7.2 vs. 2.6 months, hazard ratio
(HR) 0.43, 95% confidence interval (CI) 0.22–0.81, log-rank
test P¼ 0.009). The proportional hazard assumption was
validated, and therefore the univariate Cox regression analysis
was applied. Clinical factors statistically significant for inferior
OS included high LDH (P¼0.003), poorer PS (Po0.001), and
X2 CTCs per 7.5 ml blood (Po0.011). Treatment with a BRAF
or MAPK/ERK kinase (MEK) inhibitor was associated with
superior OS (P¼0.041), whereas treatment with Ipimulimab
was not significant for OS. Thirty-four of 75 (45%) patients in
the o2 CTCs group were alive at the time of analysis
compared with 6 of 26 (23%) patients in theX2 CTCs group.
Table 3 shows the results of the univariate Cox regression
analysis.
Multivariate Cox proportional hazards regression analyses
Multivariate Cox proportional hazards regression analysis was
performed adjusting for significant univariate factors (LDH, PS,
treatment with a BRAF or MEK inhibitor, and CTC number).
All factors identified as significant in the univariate analysis
remained significant in the multivariate analysis, except LDH.
CTC number was an independent prognostic factor for OS (HR
2.403, CI 1.303–4.430, P¼ 0.005) (Table 4). These results
were internally validated by performing bootstrapping (resam-
pling data 1,000 times; Figure 3).
Exploratory analysis of pharmacodynamic CTC changes and
prognostic significance of CTC number after treatment
Serial CTC counts were performed for 45 patients on treatment
and 28 (62%) of them exhibited pharmacodynamic changes in
CTC number. The remaining 17 patients had no CTCs at any
time points. Changes in CTC number at time-point 2 reflected
computerized tomography (CT) scan assessment performed at
6–9 weeks after commencement of treatment. All patients
whose CTC number decreased had radiological responses to
treatment (n¼ 13, dacarbazine or BRAF inhibitor). Two
responding patients had fluctuating CTC numbers between 0
and 1 after BRAF or MEK inhibitor treatment. Five patients,
whose CTC number increased, developed progressive disease.
Eight patients had stable disease while under treatment: two
Table 2. Prevalence of CTCs and association with
clinical characteristics
Patients with CTCs above
threshold
Clinical characteristic X1 X2 X3 Total patients
Age
460 24 16 13 52
o60 16 10 8 49
w2 P-value 0.222 0.236 0.332
Sex
Male 24 15 12 53
Female 16 11 9 48
w2 P-value 0.231 0.65 0.807
Mean LDH
X550 23 18 15 36
o550 17 8 6 65
w2 P-value 0.006 0.001 0.002
Performance status
P0 11 3 1 41
P1 19 14 11 45
P2 7 6 6 12
P3 1 1 1 1
w2 P-value 0.101 0.002 o0.001
Time with metastatic disease
45 Months 17 12 10 46
o5 Months 23 14 11 53
Fisher’s exact test P-value 0.544 1 1
Stage
M1a 1 0 0 4
M1b 5 3 2 18
M1c 34 23 19 79
w2 P-value 0.407 0.268 0.275
BRAF mutation (V600E)
Mutant 12 7 6 32
Wild type 14 9 6 38
Unknown 14 10 9 31
w2 P-value 0.919 0.756 0.509
Stage of treatment
First line or untreated 27 15 10 68
Second-line treatment 7 6 6 16
No treatment 6 5 5 17
w2 P-value 0.884 0.415 0.082
Abbreviations: CTC, circulating tumor cell; LDH, lactate dehydrogenase.
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displayed increases in CTC number, four had fluctuating CTC
number, and two had no CTCs until progression when their
CTCs increased to 3 and 5 CTCs per 7.5 ml blood, respec-
tively. Figure 4 shows the changes in CTC numbers for nine
BRAF mutant patients on treatment with a BRAF or MEK
inhibitor: patients A–H with a decrease in CTC number
responded to treatment, whereas patient I whose CTC number
increased progressed on treatment.
The prognostic significance of CTC number recorded before
and at any time point during treatment for all 45 patients
Table 3. Univariate Cox proportional hazards regression analysis for prediction of overall survival
At-risk group Overall survival risk
Clinical characteristic Positive Negative P-value HR 95% CI
Performance status 3 vs. 2 vs. 1 vs. 0 o0.001
LDH o550 X550 0.003 2.196 1.313–3.674
Treatment BRAF/MEK inhibitor Other/none 0.041 0.370 0.147–0.928
Baseline CTC o2 X2 o0.011 2.030 1.178–3.496
Period of time with metastasis NA1 0.059 0.983 0.965–1.001
Abbreviations: CI, confidence interval; CTC, circulating tumor cell; HR, hazard ratio; LDH, lactate dehydrogenase; MEK, MAPK/ERK kinase; NA, not applicable.
1Treated as continuous variable.
Table 4. Stepwise multivariate Cox proportion hazards regression analysis; prognostic factors considering CTC at
baseline
At-risk group Overall survival risk
Clinical characteristic Positive Negative P-value HR 95% CI
Performance status 3 vs. 2 vs. 1 vs. 0 o0.001
Treatment BRAF/MEK inhibitor Other/none 0.001 0.186 0.071–0.485
Baseline CTC o 2 X 2 0.005 2.403 1.303–4.430
Period of time with metastasis NA1 0.004 0.968 0.946–0.989
Abbreviations: CI, confidence interval; CTC, circulating tumor cell; HR, hazard ratio; MEK, MAPK/ERK kinase; NA, not applicable.
1Treated as continuous variable.
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Figure 2. Prognostic significance of circulating tumor cells (CTCs). (a) The Kaplan–Meier curve for overall survival (OS) of patients witho2 CTCs versus patients
withX2 CTCs in 7.5 ml blood at baseline. CI, confidence interval. (b) The Kaplan–Meier curve for OS of patients witho2 CTCs versus patients withX2 CTCs in
7.5 ml blood at any time point (TP) during treatment.
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confirmed longer survival for patients with o2 CTCs at any
time point during treatment (10 vs. 7 months, HR 0.34, CI
0.14–0.81, log-rank test P¼0.015; Figure 2b).
DISCUSSION
We sought to evaluate the prevalence of CTCs in metastatic
cutaneous melanoma patients and explore their utility as a
biomarker. To our knowledge, a study of CTCs in patients with
metastatic melanoma using the CellSearch (Melanoma kit)
platform with sufficient power to draw robust conclusions
regarding prognosis has not been reported previously. In an
exploratory analysis, we also asked whether pharmacody-
namic changes in CTC number were observable and whether
such changes could be potentially viewed as surrogates of
clinical response.
Our results indicate that 26% of patients had X2 CTCs at
baseline and that median OS was shorter than for those with
o2 CTCs (2.6 vs. 7.2 months, log-rank P¼ 0.009). The
population recruited into our study was heterogeneous: after
correction for confounding factors such as BRAF mutation
status, line of treatment, treatment type (targeted therapy,
Ipilimumab, chemotherapy), and time from diagnosis of
metastatic disease to study enrollment, we showed that base-
line CTC numberX2 is an independent prognostic biomarker
(P¼ 0.005). The cutoff of 2 CTCs per 7.5 ml blood that we
defined is the lowest cutoff used for the prognostic signifi-
cance of CTC number compared with small cell lung cancer
(50 CTCs), breast, prostate, and non–small cell lung cancer
(five CTCs), and colorectal cancer (three CTCs). We acknowl-
edged the critical issue of the reliability of a 2-CTC count and
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Figure 4. Pharmacodynamics of circulating tumor cell (CTC) number in individual patients A–I with BRAF mutant tumors while on treatment with a BRAF or
MEK inhibitor. Patients A–H responded to treatment, whereas patient I progressed on treatment.
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conducted an analysis of BETI (Supplementary Data online)
with respect to a CTC count of 2 CTCs per 7.5 ml blood,
demonstrating that this was a robust and reliable measure-
ment. We also internally validated the derived cutoff by
performing bootstrapping, thus limiting bias and overfitting
of the data. The only previously published data on CTC
detection using the Veridex melanoma kit reported on 44
patients with metastatic (n¼ 39) and unresected stage III
(n¼ 5) melanomas. CTC detection using this approach was
demonstrated in principle whereby 12 patients (27%) hadX2
CTCs (Rao et al., 2011).
Standards of care for advanced melanoma have changed
significantly over the past 12 months. Vemurafenib is now
licensed as first- and second-line treatment for patients harbor-
ing a BRAF V600E mutation. Ipilimumab is licensed as second-
line treatment in Europe and as first- and subsequent-line
therapy in the United States. There are currently no minimally
invasive pharmacodynamic biomarkers in routine use to
monitor early responses to these targeted treatments, nor are
there biomarkers that anticipate the onset of treatment resis-
tance. Our data suggest that CTC changes with treatment may
be an indicator of response and provide additional prognostic
value when measured sequentially during treatment.
The limitations of this study were that treatment received by
the patients was heterogeneous, reflecting standard of care
and clinical trials ongoing at the time of recruitment; imaging
was not carried out at a fixed time point and was not
consistently reported using the RECIST (Response Evaluation
Criteria In Solid Tumors) criteria. Furthermore, BRAF muta-
tional status was not assessable in 33% of patients. It remains
unclear whether the presence of a BRAF mutation is prog-
nostic and whether patients with wild-type BRAF have a worse
prognosis than those with a BRAF mutation treated with a
targeted therapy (Long et al., 2011). The small number of
patients receiving Ipilimumab and the early time points for
CTC sampling mean that no reliable conclusions can be made
for these patients. Therefore, further studies of CTCs in well-
defined subgroups of patients on the same treatment regimes
are now needed to clarify the findings presented here.
The CellSearch platform has been widely used for detection
of EpCam-positive CTCs in epithelial carcinomas. It remains
the most validated technology and the only Food and Drug
Administration-approved platform for prognostication in meta-
static breast, prostate, and colorectal disease (Cristofanilli
et al., 2004; Cohen et al., 2008; de Bono et al., 2008). The
Veridex melanoma CTC kit incorporates Melcam and HMW-
MAA antibodies respectively to capture and detect melanoma
CTCs, and only those CTCs positive for both markers are
detected. Both markers are expressed in up to 80% of
metastatic melanoma lesions (Shih, 1999; Campoli et al.,
2004). However, the level of antigen expression on tumor
cells in the circulation is unknown, particularly with regard to
detection limits by the Veridex platform. Low marker
expression may be one of the reasons why the majority of
our patients (75%) had o2 CTCs and 60% had no CTCs.
A combination of marker and marker-independent methods
may therefore be required to fully capture and interrogate
subpopulations of melanoma CTCs (De Giorgi et al., 2010).
Further CTC characterization with an additional marker
added to the standard CellSearch melanoma kit, such as NY-
ESO-1 or drug target expression, is currently possible. Muta-
tion testing in CTCs has been demonstrated in prostate cancer
(Jiang et al., 2010). It is possible that molecular subtyping
of melanoma CTCs may help define personalized treatments
for melanoma patients. Our study suggests that, in future,
molecular analysis of melanoma CTCs may aid stratification of
patients treated with targeted agents and immunotherapy and
possibly help define the best strategy for combination or
sequential treatment.
In summary, melanoma CTCs are detectable in 40% of
patients with advanced cutaneous melanoma, and the number
of CTCs detected is prognostic for overall survival. There is
preliminary evidence that changes in the number of CTCs
during treatment may reflect outcome, although further
detailed studies are required.
MATERIALS AND METHODS
Study design
Patients with newly diagnosed, untreated metastatic cutaneous
melanoma, or previously treated but with progressive disease (and a
treatment-free period of at least 6 weeks), were recruited prospec-
tively at The Christie Hospital in Manchester, United Kingdom. CTCs
were enumerated at baseline (enrollment into the study) before
treatment, after the commencement of treatment (a median of 6
weeks later, time point 2), and then up to 9, 12, and 18 weeks, and (if
applicable) at progression. Data on age, sex, PS, site of metastases,
time from diagnosis of metastatic disease to study enrollment,
treatment received after enrollment, line of treatment (first or second),
response (assessed by computerized tomography scan in all patients
and on the basis of the RECIST criteria if a trial participant), and
survival were collected. Treatment received included standard che-
motherapy with dacarbazine or targeted agents, including BRAF and
MEK inhibitors, or immunotherapy with a cytotoxic T-lymphocyte
antigen 4 monoclonal antibody. Written informed consent was
obtained from all patients and the study was ethically approved by
a regional ethics committee and the Declaration of Helsinki Princi-
ples were followed.
CTC enumeration
Peripheral blood samples were collected in 10 ml CellSave preserva-
tive tubes (Veridex), stored at room temperature, and processed
within 96 hours of collection. CTC enumeration per 7.5 ml blood
was performed according to the manufacturer’s instructions as
previously described (Rao et al., 2011). The sensitivity and
reproducibility of the CellSearch melanoma CTC kit have been
previously demonstrated (Rao et al., 2011). All images were
evaluated for assignment as CTCs and scored twice by two
experienced analysts with a reanalysis of any discrepancies in
enumeration. Previous quality assurance of CTC enumeration by
CellSearch has found interanalyst variability in image interpretation to
be the most significant factor for variation in CTC enumeration
between laboratories (Kraan et al., 2011). Validation experiments
were conducted to determine the analytical accuracy of CellSearch
CTC enumeration at low (1–10) CTC numbers. Analysts scored the
same image galleries generated from 20 different melanoma patient
samples with low CTC counts and the results were evaluated using
L Khoja et al.
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the BETI (Cummings et al., 2011) approach (see Supplementary
Material online for details).
Statistical analysis
The associations between CTC number and clinical characteristics
were examined using the w2 test and Fisher’s exact test. The w2 tests
were used for categorical clinical factors. Discrete/continuous clinical
factors were categorized using either empirical (e.g., LDH) or median
values (e.g., time period with metastatic disease) as cutoffs, and their
associations with CTC number were measured using Fisher’s exact test.
Previous reports on prognostic significance of CTC number in
metastatic carcinomas used a CTC cutoff value to categorize all
patients into ‘‘favorable’’ and ‘‘unfavorable’’ groups (Cristofanilli
et al., 2004; Cohen et al., 2008; de Bono et al., 2008; Hou et al.,
2009, 2012; Krebs et al., 2011). The optimal CTC cutoff value was
derived from baseline CTC number using a methodology similar to
that previously described (Hou et al., 2012), in which the Kaplan-
Meier analysis and the log-rank test were performed to repeatedly
examine each possible CTC cutoff, and the area under the curve of
receiver-operating characteristic curves was measured to determine
the optimal cutoff. In our study, the OS difference between patients
with favorable and unfavorable CTCs was measured by the HR
derived from multivariate Cox regression analysis, in which OS was
calculated from the date of study enrollment to death or last
follow-up. The bootstrap resampling (Efron and Tibshirani, 1993)
technique was used as internal validation to avoid potential bias and
overfitting in estimating the optimal cutoff (see Supplementary Data
online).
As prior statistically robust data on prognostic significance of CTCs
detected using the CellSearch platform in metastatic melanoma was
lacking, an interim power analysis was performed on data from the
first 65 patients. On the basis of the log-rank test, this reported a
power of 0.6 with a significance of 0.05, requiring at least an
additional 17 patients to reach a power of 0.8. Consequently, 101
patients were recruited to ensure validity of conclusions drawn from
this study.
Baseline CTC number, CTC number at time-point 2 (median of 6
weeks from commencing therapy), and clinical characteristics such as
sex, age, site of primary, LDH, PS, time from diagnosis of metastatic
disease to study enrollment, stage, BRAF mutation status, whether
treatment was first or second line, and type of treatment (Ipimulimab
or a BRAF/MEK inhibitor) were subjected to univariate Cox regression
analysis for OS. The validity of Cox regression analysis was confirmed
by testing the proportional hazard assumption as requested by
REMARK guidelines (McShane et al., 2005; Altman et al., 2012).
Significant clinical factors were subsequently included in multivariate
Cox regression analysis using a stepwise approach with inclusion
criteria P¼ 0.05 and exclusion criteria P¼ 0.1. All significant factors
excluding CTC number were applied for modeling first, and CTC-
related factors were added to the model thereafter so that the
influence of CTC-related factors was clarified. The derived
multivariate Cox model was validated using bootstrapping
(resampling data 1,000 times). The bootstrap was performed using
MATLAB R2009a (MathWorks, Natick, MA), and other statistical
analyses were performed using Statistical Package for Social Sciences
for Window version 16 (SPSS, Chicago, IL), where Pp0.05 was
deemed significant. All results were reported and validated following
the REMARK guidelines.
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